Send to

Choose Destination

See 1 citation found by title matching your search:

Heart. 2018 Jan;104(1):45-50. doi: 10.1136/heartjnl-2016-311144. Epub 2017 Jun 29.

Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome.

Author information

Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Brompton Hospital, London, UK.
NIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Hammersmith Hospitals, London, UK.
Cardiology Department, University Hospital of Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL-CIBERCV), Salamanca, Spain.
Department of Haematology, Royal Brompton Hospital, London, UK.
National Heart and Lung Institute, Imperial College School of Medicine, London, UK.
Centre for Haematology, Imperial College London, London, UK.



Although a significant proportion of patients with cyanotic congenital heart disease are thrombocytopaenic, its prevalence and clinical significance in adults with Eisenmenger syndrome (ES) is not well studied. Accordingly, we examined the relationship of thrombocytopaenia and mean platelet volume (MPV) to bleeding or thrombotic complications and survival in a contemporary cohort of patients with ES, including patients with Down syndrome.


Demographics, laboratory and clinical data were analysed from 226 patients with ES under active follow-up over 11 years.


Age at baseline was 34.6±11.4 years and 34.1% were men. Mean platelet count and MPV were 152.6±73.3×109/L and 9.6±1.2 fL, respectively. A strong inverse correlation was found between platelet count and haemoglobin concentration and MPV. During the study, there were 39 deaths, and 21 thrombotic and 43 bleeding events. On univariate Cox regression analysis, patients with a platelet count <100×109/L had a twofold increased mortality (HR 2.10, 95% CI 1.10 to 4.01, p=0.024). Platelet count was not associated with an increased risk of thrombosis. However, there was a threefold increased thrombotic risk with MPV >9.5 fL (HR 3.50, 95% CI 1.28 to 9.54, p=0.015). Patients with either severe secondary erythrocytosis (>220g/L) or anaemia (<130g/L) were at higher risk of thrombotic events (HR 3.93, 95% CI 1.60 to 9.67, p=0.003; and HR 4.75, 95% CI 1.03 to 21.84, p=0.045, respectively).


Thrombocytopaenia significantly increased the risk of mortality in ES. Furthermore, raised MPV, severe secondary erythrocytosis and anaemia, but not platelet count, were associated with an increased risk of thrombotic events in our adult cohort.


bleeding; cyanosis; eisenmenger; mean platelet volume; thrombocytopenia; thrombosis

[Indexed for MEDLINE]
Free full text

Conflict of interest statement

Competing interests: ACM has received support from the Instituto de Investigacion Biomedica de Salamanca (IBSAL). AK, KD, SJW and MAG from the Royal Brompton Hospital have received unrestricted educational and research grants and acted as consultants for Bayer, Pfizer, Actelion and GSK. LCP has received research funding and educational grants from GSK and educational grants from Actelion; no other relationships or activities that could appear to have influenced the submitted work.

Supplemental Content

Full text links

Icon for HighWire Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center